- PROFESSOR | Pathology
- PROFESSOR | Oncological Sciences
- Clinical Pathology
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
- Bladder Cancer
- Bronchoscopy, Diagnostic
- Fine Needle Biopsy
- Lung Cancer
- Needle Biopsy: Thyroid
- Squamous Cell Carcinoma
MD, Harvard Medical School
Residency, Internal Medicine
Mount Auburn Hospital
NYU Medical Center
Children's Hospital Boston
Montefiore Medical Center
We are conducting both basic and applied research in the biology of cancer cells. We are investigating the clinical utility of three tumor marker: 1) phosphorylated histone H1 (collaboration with Dr. Kohtz, Pathology); 2) glucose transporter GLUT-1 (collaboration with Dr. Haber, Medicine); 3) a ras-oncogene-induced 31kd vesicle protein (collaboration with Dr.Hanson, Pathology). These markers appear to be of clinical value in the diagnosis and management of colon, ovarian, and breast cancer, and in body-cavity effusions. We are investigating applications in these and other malignancies such as bladder carcinoma. We are also investigating mechanisms of tumor growth suppression mediated by growth factors such as nerve growth factor, and by signal transduction-regulating proteins. The aim is to uncover new diagnostic, prognostic and therapeutic advances in cancer and other diseases which result from aberrant cell proliferation.
Rathan A, Weiser KR, Pritsker A, Itzkowitz S, Bodian C, Slater G, Weiss A, Burstein D. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998 Jul 1; 83(1): 34-40.
Matsushima AY, Strauchen J, Lee G, Scigliano E, Hale EE, Weisse MT, Burstein D, Kamel O, Moore PS, Chang Y. Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus. Am J Surg Pathol 1999; 11: 1393-1400.
Weiser KR, Burstein D, Reder I, Pritsker A. GLUT1 glucose transporter expression in benign and malignant thyroid cells: An immunohistochemical study.;.
Kelman A, Rathan A, Leibowitz J, Burstein D. Thyroid cytology and the risk of malignancy in thyroid nodules: Importance of nuclear atypia in 'indeterminate' specimens.;.
Burstein D, Rathan A, Weiser K, Pritsker A, Itzkowitz S. GLUT-1 glucose transporter: A marker of neoplastic progression in colonic epithelial neoplasms.;.
Goldfischer M, Weiser K, Pritsker A, Burstein D. GLUT-1 glucose transporter expression in ovarian neoplasms: A marker of tumor progression.;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Burstein has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.